CTLA4 and neoplasm: By targeting T cells regulatory pathways, CTLA-4 monoclonal antibody has been successfully combined with mRNA vaccines in lipid/calcium/phosphate (LCP) NPs, it significantly improved anti-tumor immune response than vaccine alone (Fig. 2a; Node 4) [154].